The Motley Fool•13 Ekim 2026Vertex seen as better 2026 investment over Moderna on profitability and pipeline strength
Yahoo Finance•23 Eylül 2026Piper Sandler analyst sets $110 target for CRISPR Therapeutics, sees 86% upside
Yahoo Finance•20 Eylül 2026Three reasons why CRISPR Therapeutics stock is still a buy after a rocky 2026
Yahoo Finance•18 Eylül 2026Vertex Pharmaceuticals raises full-year revenue forecast after strong Q2 results